Author and content note: Abacus Medicine is a commercial supplier of parallel imported medicines to the UK. This article is intended solely for healthcare professionals and organisational decision-makers involved in medicines procurement or supply. It is not intended for patients or members of the public and does not provide individual medical advice.
At a glance
For those responsible for managing medicine supply, procurement, and patient safety, Brexit has introduced lasting challenges. Beyond its political implications, the UK’s departure from the EU has also created a complex regulatory and logistical environment that directly impacts medicine availability. But what does this mean for healthcare professionals and medicine procurement staff specifically, and what has changed in their work routines?
In this overview, we examine the relationship between Brexit and medicine shortages in the UK and highlight practical ways hospital pharmacy professionals can respond strategically and confidently.
How does Brexit affect medicine shortages in the UK?
The UK’s departure from the European Union changed how medicines are authorised, imported and distributed. Brexit is not the only cause of medicine shortages, but it can add complexity to an already interconnected pharmaceutical supply chain.
Regulatory divergence and market access
Following Brexit, the UK is no longer part of the European Medicines Agency (EMA), which only works within EU and EEA countries. Medicines placed on the UK market generally require the applicable MHRA authorisation, although recognition-based and other regulatory pathways may apply rather than a wholly separate assessment.
For global manufacturers of medicine, this creates a dual regulatory process that is more costly and time-consuming. As a result, some companies delay or deprioritise launching medicines in the UK, particularly for products with lower profit margins.
Customs and border processes
Post-Brexit supply routes may involve customs declarations and import controls. Depending on the product, route and UK territory, additional batch-release, certification or testing requirements may also apply.
These processes can create administrative pressure and increase the risk of delays during border clearance. The operational impact can be more significant for cold-chain and short-dated medicines, where delivery windows are limited.
Changes to European distribution networks
The UK no longer participates in the EU pharmaceutical market on the same basis as an EU member state. Distribution models designed around EU markets may therefore serve the UK through separate routes or schedules.
In practice, this can affect lead times, availability and the frequency of deliveries. It may also require suppliers and healthcare organisations to plan around different documentation and import arrangements.
The commercial position of the UK market
The UK is now a standalone market with its own regulatory obligations. For some lower-margin generics and specialist medicines, manufacturers may assess whether expected demand justifies the additional requirements.
Where companies limit or delay UK distribution, the number of available supply options may narrow. This can increase pressure when a manufacturer, product or route is disrupted.
Who is affected?
Hospital pharmacy procurement teams
Procurement teams may need to manage reduced availability, changing lead times and more frequent supplier rotation. They may also need to conduct additional sourcing or tendering activity when contracted products are unavailable.
Operational and clinical pharmacy teams
Operational teams can spend more time identifying alternatives, communicating product changes and responding to shortages. Where a medicine becomes unavailable, any substitution must remain clinically appropriate and follow local authorisation and governance requirements.
Medicines information and governance teams
Alternative products or supply routes can create additional work involving product information, documentation, batch verification and pharmacovigilance. Teams must confirm that each medicine and supply route meets the applicable UK requirements.
Senior pharmacy leaders
Senior leaders may need to balance stockholding, cost, resilience and governance. They also need clear escalation routes when supply disruption could affect service delivery or treatment continuity.
Implications for hospital pharmacy and procurement
Brexit-related supply pressures can affect several areas of hospital pharmacy operations:
AREA | POTENTIAL OPERATIONAL IMPACT |
Availability | Fewer supply options or longer lead times for some medicines. |
Procurement | More frequent sourcing, tendering and supplier changes. |
Inventory | Greater need to review safety stock, expiry risk and storage capacity. |
Governance | Additional checks for authorisation, documentation and supply routes. |
Clinical operations | More coordination when an alternative medicine or presentation is required. |
Cost control | Increased pressure where availability is limited or alternative sourcing is needed. |
The exact impact will depend on the medicine, supplier, route and UK territory. Organisations should assess each case through their established procurement, pharmacy and clinical governance processes.
How can hospital pharmacy leaders respond?
Diversifying supply options
Using more than one suitable supplier can reduce dependence on a single supply route. It can also give procurement teams more options when a product becomes unavailable. Diversification does not remove supply risk. However, it can improve flexibility when combined with current availability information and clear supplier communication.
Strengthening substitution protocols
Where clinically appropriate and locally authorised, pre-agreed substitution protocols can support a timely response when a preferred medicine is unavailable. Protocols should define professional oversight, documentation and escalation. They should not replace individual clinical judgement or local medicines governance.
Planning for longer or less predictable lead times
Stock planning may need to account for border processes and route-specific delays. This is particularly relevant for cold-chain, short-dated and time-critical medicines. Teams should balance resilience against storage capacity, expiry risk and cost. Forecasting should use current supplier information rather than fixed assumptions about delivery times.
Maintaining regulatory readiness
Internal systems should support the documentation, verification and pharmacovigilance requirements that apply to each medicine and supply route. When alternative sourcing is considered, organisations should confirm the product’s authorisation status and the licensing requirements for its import, packaging, distribution and supply.
On supply planning
A structured supply-planning approach can help hospital teams respond consistently. Organisations can review:
- Current and alternative suppliers
- Lead times and route-specific risks
- Stockholding and expiry exposure
- Cold-chain and storage capacity
- Product, pack and presentation information
- Substitution and escalation protocols
- Authorisation and documentation requirements
- Communication between procurement, pharmacy and clinical teams
Clinical, governance and purchasing decisions remain with the responsible healthcare organisations and professionals.
Key takeaway
Brexit is one of several factors that had and continues to has an impact medicine supply pressure in the UK. Regulatory divergence, border processes and separate distribution routes can affect availability, lead times and the workload of hospital pharmacy teams.
Supplier diversification, substitution planning and current supply information can support a more resilient response. Every alternative medicine and supply route must still meet the applicable authorisation, licensing and governance requirements.
Frequently asked questions (FAQ)
What are the main ways Brexit can affect UK medicine supply?
Brexit can add regulatory, customs and distribution complexity. These factors may affect market access, lead times and the number of available supply routes. The impact varies by medicine, supplier and UK territory.
Why may some medicines be harder to source after Brexit?
Separate UK packaging, authorisation or supply requirements can increase the resources needed to serve the market. Some manufacturers may therefore delay or limit UK distribution, particularly for products with lower expected commercial returns.
Can EU-sourced medicines still be used in the UK?
Yes, where the medicine has the appropriate authorisation for the relevant UK territory and is imported, packaged, documented and supplied through the applicable licensed route. The status of each medicine and supply route must be confirmed before procurement and use.
How can hospitals prepare for Brexit-related supply disruption?
Hospitals can diversify suitable suppliers, account for route-specific lead times and maintain clear substitution and escalation processes. They should also verify authorisation, documentation and licensing requirements when considering alternative products or supply routes.
Sources and further reading
We recommend the following sources for further reading for those interested in the topic.


